Andrew is a business development expert in the biotechnology and pharmaceutical industries. Most recently, he supported NewCo formation and translational efforts at The Salk Institute for Biological Studies.  Prior to Salk, Andrew developed the partnering strategy for InSphero, a Swiss biotechnology company spun out of ETH Zurich, and co-founded Nymirum, a private venture backed biotechnology company, spun out of the University of Michigan. Andrew holds a Ph.D. in Biophysics and Chemical Biology from the University of Michigan and a B.S. in Chemistry from the University of Toledo.